NFKB1 and glioblastoma: IP187B inhibits IL6/signal transducer and activator of transcription 3 (STAT3), NF-κB, and insulin-like growth factor receptor pathways and has demonstrated additive efficacy when combined with epidermal growth factor receptor (EGFR) inhibitors against primary GBM cells and intracranial GBM xenografts [28,30,31,32].